RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New antibody drug shows promise for tough blood cancers
Disease control CompletedThis early-stage trial tested a drug called flotetuzumab in 13 people with advanced blood cancers that had returned or stopped responding to treatment. The goal was to find the best dose and check for side effects. Flotetuzumab is a lab-made antibody that may stop cancer cells fr…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Promising combo for Tough-to-Treat hodgkin lymphoma shows progress
Disease control CompletedThis study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy for people whose Hodgkin lymphoma returned or didn't respond to treatment. The goal was to find the safest dose and see how many patients achieved complete remission. 45 adults…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC